Clene (CLNN) vs Rafael (RFL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Rafael (RFL) has outperformed Clene (CLNN) over the past year, losing 25.8% versus a loss of 62.0%. Over five years, RFL leads with a -84.2% price change compared with -96.3% for CLNN. Clene is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size, while Rafael is growing revenue faster (-4.7% vs -41.5%).
Rafael converts more of its revenue into profit, with a net margin of -3390.7% versus -13086.5%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | RFL |
|---|---|---|
| Share price | $3.52 | $0.9197 |
| Market cap | $50.69M | $47.99M |
| 1-day change | +0.57% | +2.19% |
| YTD return | -40.03% | -22.06% |
| 1-year return | -62.03% | -25.83% |
| 5-year return | -96.28% | -84.19% |
| EPS (TTM) | $-2.30 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $200.00K | $874.00K |
| Revenue growth (YoY) | -41.52% | -4.69% |
| Net income (latest FY) | $-26.17M | $-29.64M |
| Gross margin | 78.50% | — |
| Operating margin | -11541.50% | -3822.54% |
| Net margin | -13086.50% | -3390.73% |
| 52-week high | $10.84 | $3.96 |
| 52-week low | $3.02 | $0.781 |
| Distance from 52-week high | -67.53% | -76.78% |
| Analyst consensus | none | — |
| Avg. price target upside | +814.77% | — |
| Average volume | 115.06K | 140.84K |
| Shares outstanding | 14.40M | 51.39M |
| Employees | 76 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RFL has outperformed CLNN by 36.2 percentage points over the past year.
- Rafael is more profitable, keeping -3390.7 cents of every revenue dollar as net income versus -13086.5 cents for Clene.
- Rafael grew revenue faster in its latest fiscal year (-4.69% vs -41.52%).
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Rafael
RFL stock →Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
CLNN vs RFL FAQ
Which is bigger, Clene or Rafael?
Clene (CLNN) is larger, with a market capitalization of $50.69M compared with $47.99M for Rafael (RFL).
Which stock has performed better over the past year, CLNN or RFL?
RFL returned -25.83% over the past 12 months, compared with -62.03% for CLNN (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Rafael in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.